ReviewCurrent neurology and neuroscience reports2002
Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development.
Review in Current neurology and neuroscience reports, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 59 citations in OpenAlex.
- Translational profiling identifies sex-specific metabolic and epigenetic reprogramming of cortical microglia/macrophages in APPPS1-21 mice with an antibiotic-perturbed-microbiome.Molecular neurodegeneration · 2023Article
- Article
- Modeling of Neurodegenerative Diseases: 'Step by Step' and 'Network' Organization of the Complexes of Model Systems.International journal of molecular sciences · 2022Review
- Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology.Nature communications · 2022Article
- Impaired Experience-Dependent Refinement of Place Cells in a Rat Model of Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2022Article
- Sex-specific effects of microbiome perturbations on cerebral Aβ amyloidosis and microglia phenotypes.The Journal of experimental medicine · 2019Article
- CRISPR/Cas9 Technology as an Emerging Tool for Targeting Amyotrophic Lateral Sclerosis (ALS).International journal of molecular sciences · 2018Review
- Individual and temporal variability of the retina after chronic bilateral common carotid artery occlusion (BCCAO).PloS one · 2018Article
- Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice.PloS one · 2017Article
- No apparent transmission of transgenic α-synuclein into nigrostriatal dopaminergic neurons in multiple mouse models.Translational neurodegeneration · 2015Article
- Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2013Article
- Treatment with D3 removes amyloid deposits, reduces inflammation, and improves cognition in aged AβPP/PS1 double transgenic mice.Journal of Alzheimer's disease : JAD · 2013Article
- Alzheimer's therapeutics: translation of preclinical science to clinical drug development.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Review
- A kinetic aggregation assay allowing selective and sensitive amyloid-β quantification in cells and tissues.Biochemistry · 2011Article
- Activation of ERK by spontaneous seizures in neural progenitors of the dentate gyrus in a mouse model of epilepsy.Experimental neurology · 2010Article
- Discovery and characterization of a mammalian amyloid disaggregation activity.Protein science : a publication of the Protein Society · 2010Article
- Cardiomyocyte contractile dysfunction in the APPswe/PS1dE9 mouse model of Alzheimer's disease.PloS one · 2009Article
- The insulin paradox: aging, proteotoxicity and neurodegeneration.Nature reviews. Neuroscience · 2008Review
- Gait analysis detects early changes in transgenic SOD1(G93A) mice.Muscle & nerve · 2005Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases present an extraordinary challenge for medicine due to the grave nature of these illnesses, their prevalence, and their impact on individuals and caregivers. The most common of these age-associated chronic illnesses are Alzheimer's disease (AD) and Parkinson's disease (PD); other examples include the prion disorders, amyotrophic lateral sclerosis (ALS), and the trinucleotide (CAG) repeat diseases. All of these diseases are characterized by well-defined clinical syndromes with progressive courses that reflect the dysfunction and eventual loss of specific neuronal populations. Current therapies provide only symptomatic relief; none significantly alter the course of disease. We describe here how transgenic mice designed to model these diseases have substantially contributed to the identification and validation of many promising new therapies, and conversely how they have quickly and cost effectively eliminated several targets with unrealized expectations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.